MONDAY, May 17 (HealthDay News) -- Roxro Pharma's Sprix (ketorolac tromethamine) nasal spray has been approved by the U.S. Food and Drug Administration for the short-term treatment of moderate to moderately severe pain, the manufacturer said Monday in a news release.
The nasal spray contains the non-steroidal anti-inflammatory drug (NSAID) ketorolac. The non-narcotic medication minimizes the chances for abuse and eliminates side effects associated with narcotic pain relievers, the drug maker said.
The drug should not be used for longer than five days. Potential side effects may include peptic ulcers or gastrointestinal bleeding, and the drug shouldn't be used in people who already have these conditions, a high risk of bleeding, or advanced renal failure, the company said.
Roxro is based in Menlo Park, Calif.
More information
The U.S. National Library of Medicine has more about pain relievers.
